Jia Wei

Jia Wei

Auto-generated profile, based on publicly available information

Jia Wei

Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
JWJia Wei
Jia Wei
LYLu Yang
Lu Yang
YWYi-Ning Wu
Yi-Ning Wu
JXJian Xu
Jian Xu
Background: Pancreatic cancer (PC) is a highly malignant tumor with no effective early diagnostic biomarkers. This study was performed to screen and identify serum microRNAs (miRNAs) as noninvasive biomarkers for PC diagnosis.

28 April 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MXMengxiao Xie
Mengxiao Xie
JWJia Wei
Jia Wei
JXJian Xu
Jian Xu
Lung cancer is the leading cause of cancer-associated deaths worldwide, with non-small cell-lung cancer (NSCLC) accounting for approximately 80% of cases. Immune escape has been demonstrated to play a key role in the initiation and progression of NSCLC, although the underlying mechanisms are diverse and their puzzling nature is far from being understood. As a critical participant in immune escape, the CD4+ T cell subset of regulatory T (Treg) cells, with their immunosuppressive functions, has been implicated in the occurrence of many types of cancers. Additionally, therapies based on Treg blockade have benefited a portion of cancer patients, including those with NSCLC. Accumulating literature has noted high Treg infiltration in NSCLC tumor tissues, bone marrow, lymph nodes and/or blood; moreover, the tumor milieu is involved in regulating the proliferation, differentiation, recruitment and suppressive functions of Treg cells. Multifarious mechanisms by which CD4+ Treg cells are generated, attracted and modulated in the NSCLC milieu will be discussed in this review.

1 August 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YWYining Wu
Yining Wu
JWJia Wei
Jia Wei
WZWei Zhang
Wei Zhang
MXMengxiao Xie
Mengxiao Xie
XWXueying Wang
Xueying Wang
JXJian Xu
Jian Xu
Purpose: Lung cancer is a leading cause of cancer-related death, with lung adenocarcinoma (LUAD) representing the most common subtype. Recently, exosome-based biomarkers have provided new diagnostic approaches for malignancies. We aimed to identify specific exosomal microRNAs (miRNAs) as noninvasive biomarkers for LUAD. Patients and Methods: A total of 110 participants were enrolled and randomly divided into two sets: the discovery set (n=20) and the validation set (n=90). Exosomes were isolated from serum, and miRNAs were subsequently extracted. Candidate miRNAs (miR-21, miR-221-3p, miR-222-3p, miR-223, miR-638 and miR-1290) were detected by quantitative real-time PCR (qRT-PCR) in the discovery set. The upregulated miR-1290 was then selected for further analysis in the validation set along with three tumor markers (CEA, CYFRA21-1 and NSE). The diagnostic and prognostic value of exosomal miR-1290 were estimated through receiver-operating characteristic (ROC) and survival analysis. Results: Serum exosomal miR-1290 was significantly upregulated in LUAD patients compared to healthy controls (P< 0.001) and decreased after resection (P=0.0029). Its expression level was associated with tumor stage, tumor size, lymph node and distant metastasis (all P < 0.05). Exosomal miR-1290 had a higher diagnostic efficacy than CEA, CYFRA21-1 and NSE, with a sensitivity of 80.0% and specificity of 96.7% (AUC: 0.937, 95% CI: 0.890– 0.985; P< 0.001). Moreover, LUAD patients with a high level of exosomal miR-1290 had significantly poorer progression-free survival (PFS) than those with a low level of exosomal miR-1290 (mean PFS: 14 months vs 37 months, P< 0.001). Cox proportional hazards model analysis demonstrated that exosomal miR-1290 could be an independent risk factor for the prognosis of LUAD (HR=7.80, P=0.017). Conclusion: Serum exosomal miR-1290 could be a potential diagnostic and prognostic biomarker for LUAD.

1 June 2010 in Lung Cancer
Verified
Journal Article
Closed access
ECEnric Carcereny
Enric Carcereny
JRJose Luis Ramirez
Jose Luis Ramirez
MSMaria Sanchez-Ronco
Maria Sanchez-Ronco
DIDolores Isla
Dolores Isla
MCManuel Cobo
Manuel Cobo
RRRafael Rosell
Rafael Rosell

1 August 2019 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JWJia Wei
Jia Wei
YWYi-Ning Wu
Yi-Ning Wu
YLYun Ling
Yun Ling
XCXiao-Ting Chen
Xiao-Ting Chen
QZQiong Zhu
Qiong Zhu
JXJian Xu
Jian Xu

1 June 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JWJia Wei
Jia Wei
RYRuixia Yang
Ruixia Yang
QYQin Ye
Qin Ye
XXXue-Lian Xiao
Xue-Lian Xiao
XZXiao-Ling Zang
Xiao-Ling Zang
JLJiang Li
Jiang Li